Vorapaxar

DRUG9 trials

Conditions

AtherosclerosisCerebrovascular AccidentCoronary Artery DiseaseDiabetes MellitusHIVHealthy VolunteersIschemiaMyocardial Infarction

Phase 1

Attenuation of D-dimer Using Vorapaxar to Target Inflammatory and Coagulation Endpoints

CompletedNCT02394730

Kirby InstituteHIV

Start: 2015-09-30End: 2018-01-31Updated: 2019-03-06

Phase 2

Trial to Assess the Safety and Effects of Vorapaxar in Japanese Subjects With Acute Coronary Syndrome (P04772; MK-5348-016)

CompletedNCT00684203

Merck Sharp & Dohme LLCAtherosclerosis, Myocardial Infarction, Myocardial Ischemia

Start: 2006-12-01End: 2007-10-01Updated: 2017-05-05

Phase 3

Trial to Assess the Effects of Vorapaxar (SCH 530348; MK-5348) in Preventing Heart Attack and Stroke in Patients With Atherosclerosis (TRA 2°P - TIMI 50) (P04737)

CompletedNCT00526474

Merck Sharp & Dohme LLCAtherosclerosis, Cerebrovascular Accident, Ischemia +2

Start: 2007-09-01End: 2011-12-01Updated: 2018-09-21

Trial to Assess the Effects of Vorapaxar (SCH 530348; MK-5348) in Preventing Heart Attack and Stroke in Particpants With Acute Coronary Syndrome (TRA•CER) (Study P04736)

TerminatedNCT00527943

Merck Sharp & Dohme LLCAtherosclerosis, Myocardial Infarction, Myocardial Ischemia

Start: 2007-12-01End: 2011-07-01Updated: 2018-09-21

Phase 4

Vorapaxar in Patients With Prior Myocardial Infarction Treated With Prasugrel and Ticagrelor

CompletedNCT02545933

University of FloridaMyocardial Infarction

Start: 2016-02-29End: 2020-01-31Updated: 2020-09-16

Vorapaxar as an Add-On Antiplatelet Therapy in Patients With and Without Diabetes Mellitus

CompletedNCT02548650

University of FloridaDiabetes Mellitus, Myocardial Infarction, Peripheral Arterial Disease

Start: 2016-03-25End: 2019-02-14Updated: 2020-02-12

Vorapaxar in the Human Endotoxemia Model

CompletedNCT02875028

Medical University of ViennaHealthy Volunteers

Start: 2016-06-30End: 2016-11-30Updated: 2020-01-10

Vorapaxar and Lower Extremity Bypass Grafts

WithdrawnNCT02975583

Vanderbilt UniversityPeripheral Artery Disease

Start: 2017-10-01End: 2018-01-10Updated: 2018-01-25

Vorapaxar on Thrombin Generation and Coagulability

CompletedNCT03207451

Inova Health Care ServicesCoronary Artery Disease, Myocardial Infarction, Peripheral Vascular Disease

Start: 2016-01-01End: 2018-08-01Updated: 2022-08-18

2022-11-0127 citations

Cardiovascular Biomarkers and Heart Failure Risk in Stable Patients With Atherothrombotic Disease: A Nested Biomarker Study From TRA 2°P‐TIMI 50

Journal of the American Heart Association2021-04-228 citations

Pharmacodynamic Effects of Vorapaxar in Prior Myocardial Infarction Patients Treated With Potent Oral P2Y<sub>12</sub> Receptor Inhibitors With and Without Aspirin: Results of the VORA-PRATIC Study.

2020-04-2014 citations

Effect of vorapaxar on cardiovascular and limb outcomes in patients with peripheral artery disease with and without coronary artery disease: Analysis from the TRA 2°P-TIMI 50 trial

Vascular Medicine2020-01-3037 citations

Efficacy and safety of vorapaxar for secondary prevention in low body weight in patients with atherosclerosis: analyses from the TRA 2°P-TIMI 50 Trial

European Heart Journal Acute Cardiovascular Care2019-10-238 citations

Pharmacodynamic Effects of Vorapaxar in Patients With and Without Diabetes Mellitus: Results of the OPTIMUS-5 Study.

2019-09-0112 citations

Vorapaxar for HIV-associated inflammation and coagulopathy (ADVICE): a randomised, double-blind, placebo-controlled trial.

2018-09-2315 citations

Prognostic and Practical Validation of Current Definitions of Myocardial Infarction Associated With Percutaneous Coronary Intervention.

2018-05-0121 citations

Peripheral Revascularization in Patients With Peripheral Artery Disease With Vorapaxar: Insights From the TRA 2°P-TIMI 50 Trial.

2016-10-0128 citations

Atherothrombotic Risk Stratification and the Efficacy and Safety of Vorapaxar in Patients With Stable Ischemic Heart Disease and Previous Myocardial Infarction

Circulation2016-07-21167 citations

Universal Classification System Type of Incident Myocardial Infarction in Patients With Stable Atherosclerosis: Observations From Thrombin Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events (TRA 2°P)‐TIMI 50

Journal of the American Heart Association2016-07-0618 citations

Validation of BARC Bleeding Criteria in Patients With Acute Coronary Syndromes: The TRACER Trial.

2016-05-0178 citations

Lack of Concordance Between Local Investigators, Angiographic Core Laboratory, and Clinical Event Committee in the Assessment of Stent Thrombosis

Circulation Cardiovascular Interventions2016-05-0114 citations

Acute Limb Ischemia and Outcomes With Vorapaxar in Patients With Peripheral Artery Disease

Circulation2016-01-30191 citations

Efficacy and Safety of Vorapaxar With and Without a Thienopyridine for Secondary Prevention in Patients With Previous Myocardial Infarction and No History of Stroke or Transient Ischemic Attack

Circulation2015-09-0438 citations

Meta-analysis of intracranial hemorrhage in acute coronary syndromes: incidence, predictors, and clinical outcomes.

2015-06-1818 citations

Magnitude of Troponin Elevation and Long-Term Clinical Outcomes in Acute Coronary Syndrome Patients Treated With and Without Revascularization

Circulation Cardiovascular Interventions2015-05-3033 citations

Efficacy and Safety of Vorapaxar as Approved for Clinical Use in the United States

Journal of the American Heart Association2015-03-1074 citations

Vorapaxar in Patients With Diabetes Mellitus and Previous Myocardial Infarction

Circulation2015-02-1478 citations

Coronary stent thrombosis with vorapaxar versus placebo: results from the TRA 2° P-TIMI 50 trial.

2014-12-0126 citations

7 more papers not shown